Rxo (RXO) Price to Earnings (2022 - 2026)

Rxo (RXO) has reported Price to Earnings for 5 consecutive years, with 505.57 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings fell 76.53% year-over-year to 505.57; the trailing twelve-month figure through Jun 2026 stood at 43.33 (down 417.81% YoY), and the FY2025 full-year result was 20.75, down 89.2% from the prior year.
• Price to Earnings slipped to 505.57 in Q2 2026 per RXO's latest filing, from 66.95 in the prior quarter.
• Across five years, Price to Earnings topped out at 1361.01 in Q4 2023 and bottomed at 2308.45 in Q3 2023.
• Historically, Price to Earnings has averaged 179.0 across 5 years, with a median of 149.3 in 2024.
• The sharpest annual moves came in 2023 and 2025: Price to Earnings surged 371.92% in 2023, then sank 873.05% in 2025.
• Over 5 years, Price to Earnings stood at 500.52 in 2022, then soared by 371.92% to 1361.01 in 2023, then plunged by 109.35% to 127.22 in 2024, then jumped by 64.54% to 45.11 in 2025, then plunged by 1020.79% to 505.57 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 505.57, 66.95, and 45.11 for Q2 2026, Q1 2026, and Q4 2025 respectively.